

Supported by*

- syngo DynaCi
- syngo DynaCT 360
- syngo Fusion
- syngo 3D Roadmap
- syngo Needle Guidance
- syngo Neuro PBV IR
- syngo DynaPBV Body
- syngo Embolization Guidance
- syngo iFlow
- syngo DualVolume
- syngo Dyna4D
- syngo DynaCT SMART
- syngo Dyna3D

Courtesy of

Jeff McCann, M.D., Ronan Ryan, M.D., Department of Interventional Radiology, St. Vincent University Hospital, Dublin, Ireland

System & Software

Artis Q ceiling VD10 syngo X Workplace VC10

*This list of applications is not complete. Not all applications available for all software versions

Case Description

Patient History

51-year-old male with Hep C. Hepatocellular BCLC stage A carcinoma (HCC), which is not amenable to radiofrequency (RF) ablation due to its proximity to the gall bladder. Patient is awaiting liver transplant and recommended for TACE treatment.

Diagnosis

Pre-procedural four-phase CT of the liver measured a maximum of 3.5 cm in length of the segment V HCC lesion. The lesion demonstrated arterial hyperenhancement with portal venous and delayed phase washout centrally consistent with a HCC.

Treatment

Selective chemoembolization of the 3.5 cm segment V HCC was performed on the patient. Chemoembolization was performed using 150 mg Doxorubicin adsorbed upon two vials of 100-300 μ m DC Beads, followed by bland embolization

using approximately 30 % of one vial of 500-700 μ m Embosphere microspheres. The patient tolerated the procedure well and there were no immediate complications.

General Comments

The pre-embolization *syngo* DynaPBV Body showed that the hypervascular tumor in the inferior right lobe derived supply from the segment V artery. Chemoembolization followed by bland embolization of the arterial supply was satisfactory with excellent angiographic response. The post-embolization PBV run confirmed complete treatment by showing no contrast opacification within the tumor.

Tips and Tricks


Don't oversedate the patient as patient cooperation with breathing is very important. Arms should be put above the head during *syngo* DynaPBV Body acquisition.

The post-embolization *syngo* DynaPBV acquisition confirmed complete treatment by showing no contrast opacification within the tumor. The one-month follow-up four-phase CT liver imaging confirmed results indicated by *syngo* DynaPBV Body.


Transarterial chemoembolization of HCC using syngo DynaPBV Body

Acquisition Protocol	5s DynaPBV Body (automatic)	Reconstruc
		VOI Size:
Injection Protocol		Slice Matrix
Contrast Media (CM):	340 mg Iodine/ml	Kernel Type
Dilution:	33 %	Image Char
njection Volume (CM/Saline):	36 ml (12ml/24ml)	Reconstruct
Power Injector Used:	Yes	Viewing Pre
njection Rate:	3 ml/s	Secondary
Ouration of Injection:	12 s	
X-ray Delay:	Manual CM injection started when C-arm finished mask run 7 s acquisition delay as C-arm returns for fill run	VOI Size:
		Slice Matrix
		Kernel Type
		Image Char
Catheter Position:	Proper hepatic	Reconstruct
		Viewing Pre

Reconstruction Protocol	DynaPBV Body Dual PBV	
VOI Size:	Large	
Slice Matrix:	512X512	
Kernel Type:	HU	
Image Characteristics:	Smooth	
Reconstruction Mode:	Dual (Sub and Mask)	
Viewing Preset:	PBV Body	
Secondary Recon	Reconstruct the Nat Fill run	
VOI Size:	Large	
Slice Matrix	=401/=40	
JIICE WALTIA.	512X512	
Kernel Type:	512X512 HU	
Since Matrixi		
Kernel Type:	ни	



Secondary reconstruction of the fill run of the pre-procedural *syngo* DynaPBV Body run gives good visualization of vessel tree (esp. showing the looped tumor-feeding vessel).



Pre- and post-embolization syngo DynaPBV imaging to confirm treatment success.

The statements by Siemens' customers presented here are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption), there can be no guarantee that other customers will achieve the same results.

On account of certain regional limitations of sales rights and service availability, we cannot guarantee that all products included in this case are available throughout the Siemens sales organization worldwide.

All rights reserved.

Siemens Healthcare Headquarters

Siemens Healthcare GmbH Henkestr. 127 91052 Erlangen Germany

Phone: +49 9131 84-0 siemens.com/healthcare

PDF only. | © Siemens Healthcare GmbH, 2016